pharma · Congenital Adrenal Hyperplasia · Carcinoid Syndrome · CRNX
Crinetics Pharmaceuticals Europe
Crinetics Pharmaceuticals Europe GmbH
Crinetics Pharmaceuticals Europe clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 6055 Lusk Blvd, San Diego, California 92121, US
- Founded
- 2008
- Employees
- 597
- Programs
- 12
- Drugs
- 4
- Patents
- 26
Crinetics Pharmaceuticals Europe projects
4 ClinicalTrials.gov programs sponsored by Crinetics Pharmaceuticals Europe.
Crinetics Pharmaceuticals Europe has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CRN09682
Crinetics Pharmaceuticals Europe GmbH
SST2-positive Neuroendocrine Neoplasms
1 trial -
Randomized: 40 mg Paltusotine
Crinetics Pharmaceuticals Europe GmbH
Carcinoid Syndrome
1 trial -
atumelnant
Crinetics Pharmaceuticals Europe GmbH
Cushing Syndrome
1 trial -
atumelnant (CRN04894)
Crinetics Pharmaceuticals Europe GmbH
Congenital Adrenal Hyperplasia
2 trials
Frequently asked questions
How many clinical projects does Crinetics Pharmaceuticals Europe have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.